CDT Equity (CDT) Operating Income (2022 - 2026)
CDT Equity's (CDT) quarterly Operating Income came in at -$3.7 million in Q1 2026, down 1.11% YoY from -$3.7 million in Q1 2025, and up 82.75% on a QoQ basis from -$21.2 million in Q4 2025.
CDT Equity (CDT) Operating Income (2022 - 2026) Analysis & Trends
CDT Equity (CDT) has 5 years of Operating Income data on file, last reported at -$3.7 million in Q1 2026.
- Quarterly Operating Income fell 1.11% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.8 million (down 129.38% YoY) and the FY2025 annual result came in at -$36.8 million, down 138.96% from the prior year.
- Operating Income improved to -$3.7 million in Q1 2026, from -$21.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$263718.0 in Q1 2022 to a low of -$21.2 million in Q4 2025.
- A 5-year average of -$3.8 million and a median of -$3.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 53.91% — and 2024, when it tumbled 1251.4%.
- Tracing CDT's Operating Income over 5 years: stood at -$1.7 million in 2022, then plunged by 45.1% to -$2.4 million in 2023, then slumped by 43.85% to -$3.5 million in 2024, then slumped by 506.73% to -$21.2 million in 2025, then surged by 82.75% to -$3.7 million in 2026.
- The last three Operating Income figures came in at -$3.7 million (Q1 2026), -$21.2 million (Q4 2025), and -$7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 133.12 Mn |
| 10 | CDT Equity | 1.57 Mn | 1.57 Mn | - | -3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.00 Mn |
| Mar 31, 2026 | -3.66 Mn |
| Dec 31, 2025 | -21.20 Mn |
| Sep 30, 2025 | -7.03 Mn |
| Jun 30, 2025 | -4.95 Mn |
| Mar 31, 2025 | -3.62 Mn |
| Dec 31, 2024 | -3.49 Mn |
| Sep 30, 2024 | -5.81 Mn |
| Jun 30, 2024 | -3.14 Mn |
| Mar 31, 2024 | -2.96 Mn |
| Dec 31, 2023 | -2.43 Mn |
| Sep 30, 2023 | -430,000.00 |
| Jun 30, 2023 | -888,000.00 |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -1.67 Mn |
| Sep 30, 2022 | -933,000.00 |
| Jun 30, 2022 | -279,420.00 |
| Mar 31, 2022 | -263,718.00 |